IMMX Company Profile and Key Details

Immix Biopharma, Inc. has 28.83 million shares outstanding. The public float is 19.04 million shares, elevated short interest at 1.18% of float. This equals 195.16 thousand shares. The short ratio is 0.93 days. Institutional investors hold 12.89% of the float. Insiders own 34.4%. Rachman Ilya M holds 1.14 million shares, Torchilin Vladimir P has 905.20 thousand shares and Senn Sean has 899.80 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Immix Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.82. This means the shares are trading above this model’s fair value.

Immix Biopharma, Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is -43.61%. Wall Street analysts project EPS growth of 16.92% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.14. Next year's EPS is expected at -$11.32. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $8.00. The high target offers 133.5% upside. The low target suggests -18.78% downside. The mean target is $16.11. This offers 63.55% upside. Immix Biopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by 26.32%. The prior quarter beat by 4.76%. Over the last six quarters, Apple has recorded several small beats. These include -28.57% in August 12, 2024.

IMMX has shown sold momentum, gaining 3.6% over the past week and 60.28% over the past quarter, though year-to-date performance is down -12.05%. Short-term trend indicators are bearishly aligned (SMA20 18.32%, SMA50 40.13%, SMA200 133.52%). The stock’s 14-day RSI is 70.58 (overbought), while the ATR of 0.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.35% below its high and over 533.58% above its low. Average 10-day trading volume of 624.63 thousand shares is below the 3-month average of 834.08 thousand, indicating normal recent market interest.

Immix Biopharma, Inc. (NASDAQ:IMMX) closed at $9.86 USD, losing -$0.18 (-1.79%) from the previous close of $10.04. The stock is currently mid-range between its 52-week high and low $1.60 and $11.61. With a market capitalization of about $522.23 million, Immix Biopharma, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.21). Key stats such as the average daily volume over the past year has been around 825.78 thousand shares, volume is running light vs its 52-week average. Headquartered in Los Angeles, CA, Immix Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ilya Rachman, the company employs approximately 18 people and listed since December 16, 2021. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.

Immix Biopharma, Inc. trades at a P/E ratio of -12.76, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.0 trading at moderately above to book value. The P/FCF stands at -21.07, also below market averages.

Immix Biopharma, Inc. (NASDAQ:IMMX) shares are down -12.05% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Immix Biopharma, Inc. trading at a premium to the broader market with a P/E of -12.76. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $12.33, suggesting 25.18% upside. Our AI forecast model points to short-term weakness (-2.84% over two weeks), a medium-term rise (201.22% over three months), and a longer-term gain (230.36% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Immix Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.84%, with price expected at $9.57 by April 28, 2026, within a range of $8.82 to $10.36 3-Month Outlook: Projected rise of 201.22%, reaching $29.67 by July 13, 2026, with a range of $29.47 to $29.94. 1-Year Outlook: Projected gain of 230.36%, with price at $32.54 by April 14, 2027, within a range of $34.25 to $35.99.